Национальный журнал Глаукома

Расширенный поиск

Сравнительная характеристика антиоксидантной активности аналогов простагландинов для местного лечения глаукомы

Полный текст:

Об авторах

Наталия Ивановна Курышева
Центр офтальмологии ФМБА России, Клиническая больница №86

О. А. Азизова
НИИ физико-химической медицины ФМБА России

А. П. Пирязев
НИИ физико-химической медицины ФМБА России

Список литературы

1. Kumar D.M., Agarwal N. Oxidative stress in glaucoma: a burden of evidence. J Glaucoma 2007; 16(3):334-343.

2. Sao^ S.C., Pascotto A., Camicione P., Capris P., Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol 2005; 123(4):458-463.

3. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 2006; 25(5):490-513.

4. Zanon-Moreno V., Marco-Ventura P., Lleo-Perez A., Pons- Vazquez S. Oxidative stress in primary open-angle glaucoma. J Glaucoma 2008; 17(3):263-268.

5. Lieven C.J., Vrabec J.P., Levin L.A. The effects of oxidative stress on mitochondrial transmembrane potential in retinal ganglion cells. Antioxid Redox Signal 2003; 5(3):641-646.

6. Tezel G., Luo C., Yang X. Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in human retina and optic nerve head. Invest Ophthalmol Vis Sci 2007; 48(3):1201-1211.

7. Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled trials. J Glaucoma 2008; 17(7):667-673.

8. Gandolfi S., Simmons S., Sturm R. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001; 18(2):110-121.

9. Konstas A., Hollo G., Irkec M., Melamed S. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. Br J Ophthalmol 2007; 91(6):757-760.

10. McCullough L., et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004; 24: 257-268.

11. Odani N., Seike H., Kurashima H. Protective effect of latano- prost on glutamate-induced cytotoxicity. World Glaucoma Congress. Singapore. Abstract Book 2007; 184-185.

12. Osborne N.N., Ji D., Abdul Majid A.S., Fawcett R.J., Sparatore A., Del Soldato P. ACS67, a hydrogen sulfide-releasing derivative of latanoprost acid, 106 attenuates retinal ischemia and oxidative stress to RGC-5 cells in culture. Invest Ophthalmol Vis Sci 2005; 51: 284-294.

13. Drago F., Valzelli S., Emmi I., Marino A., Scalia C., Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp Eye Res 2001; 72(4):479-486.

14. Zheng J., Feng X., Hou L., Cui Y., Zhu L., Ma J. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway. Cell Mol Neurobiol 2011; 31(4):597-604.

15. Yamagishi R., Aihara M., Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Exper Eye Res 2011; 93:265-270.

16. Hutchinson A.J., Chou C.L., Israel D.D., Xu W., Regan J.W. Activation of EP2 prostanoid receptors in human glial cell lines stimulates the secretion of BDNF. Neurochem Int 2009; 54:439-446.

17. Choi S.H., Aid S., Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 2009; 30:174-181.

18. Inan U., Ermis S., Orman A., Onrat E., Yucel A. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J Ocular Pharmacol Ther 2004; 20(4):293-310.

19. Martinez A., Sanchez M. Predictive value of colour Doppler imaging in a pro- spective study of visual field progression in primary open-angle glaucoma. Acta Ophthalmol Scand 2005; 83:716-722.

20. Koz O., Ozsoy A., Yarangumeli A., Kose S., Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand 2007; 85:838-843.

21. Akarsu C., Bilgili Y.K., Taner P., Unal B., Ergin A. Short-term effect of latanoprost on ocular circulation in ocular hypertension. Clin Exp Ophthalmol 2004; 32:373-377.

22. Zeitz O., Matthiessen E.T., Reuss J., Wiermann A., Wagenfeld L., Galambos P., Richard G., Klemm M. Effects of glaucoma drugs on ocular haemodynamics in normaltension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide. BMC Ophthalmol 2005; 5:6.

23. Inan U.U., Ermis S.S., Yucel A., Ozturk F. The effects of latano- prost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. Acta Ophthalmol Scand 2003; 81:155-160.

24. Astin M., Stjernschantz J., Selen G. Role of nitric oxide in PGF2-a-induced ocular hyperaemia. Exp Eye Res 1994; 59:401-407.

25. Ishii K., Tomidokoro A., Nagahara M., Tamaki Y., Kanno M., Fukaya Y. et al. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest Ophthalmol Vis Sci 2001; 42:2957-2963.

26. Izzotti A., Sacd S.C., Longobardi M., Cartiglia C. Sensitivity of ocular anterior chamber tissues to oxidative damage and its relevance to the pathogenesis of glaucoma. Invest Ophthalmol Vis Sci 2009; 50(11):5251-5258.

27. Алексеев В.Н., Мартынова Е.Б. и др. Значение митохондриальной патологии в медицине и в офтальмологии (обзор). Российская глаукомная школа. Глаукома: теория и практика: Сб. научн. труд. СПб., 2011; 5-11. [Alekseev V.N., Martynova E.B., et al. The value of mitochondrial abnormality in medicine and ophthalmology (review). Russian glaucoma school. Glaucoma: theory and practice: Sat. nauchn. work. SPb., 2011; 5-11. (In Russ.)].

28. Mittag T.W., Danias J., Pohorenec G., Yuan H.M., Burakgazi E., Chalmers-Redman R. et al. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 2000; 41:3451-3459.

29. Tezel G., Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest Ophthalmol Vis Sci 2004; 45:4049-4059.

30. Abu-Amero K., Morales J., Bosley T. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2006; 47(10):2533-2541.

31. Giasson B.I., et al. Oxidative damage linked to neurodegeneration by selective -synuclein nitration in synucleinopathy lesions. Science 2000; 29:985-989.

32. McKinnon S.J., Glaucoma: ocular Alzheimer’s disease? Frontiers in Bioscience 2003; 8(1):140-156.

33. Flammer J., Haefliger I.O., Orgul S., Resink T. Vascular dys- regulation: a principal risk factor for glaucomatous damage? J Glaucoma 1999; 8:212-219.

34. Murphy M.P. Nitric oxide and cell death. Biochimica et Bio- physica Acta 1999; 1411:401-414.

35. Бунин А.Я., Бабиджаев М.А., Супрун А.В. Об участии перекисного окисления липидов в деструкции дренажной системы глаз при открытоугольной глаукоме. Вестн. офтальмол. 1984; 2:13-16. [Bunin A.Ya., Babidzhaev M.A., Suprun A.V. On participation of lipid peroxidation in the destruction of the drainage system in eyes with open-angle glaucoma. Vestn Oftalmol 1984; 2:13-16. (In Russ.)].

36. Курышева Н.И., Винецкая М.И., Еричев В.П., Демчук М.Л. Роль свободно-радикальных реакций камерной влаги в развитии первичной открытоугольной глаукомы. Вестн. офтальмол. 1996; 4:3-5. [Kurysheva N.I., Vinetskaya M.I., Erichev V.P., Demchuk M.L. The role of intraocular fluid free- radical reactions in the development of primary open-angle glaucoma. Vestn Oftalmol 1996; 4:3-5. (In Russ.)].

37. Lipton P. Ischemiccell death in brain neurons. Physiol Rev 1999; 79:1431-1568.

38. Izzotti A., Sacd S.C., Di Marco B., et al. Antioxidant activity of timolol on endothelial cells and its relevance for glaucoma course. Eye (Lond) 2008; 22(3):445-453.

39. Zanon-Moreno V., Garcia-Medina J.J., Gallego-Pinazo R., Vinuesa-Silva I. Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. Eur J Ophthalmol 2009; 19(4):565-571.

40. Ozdemir G., Ozdemir G., Tolun F., Gul M., Imrek S. Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation. J Glaucoma 2009; 18:662-665.

41. Курышева Н.И., Деева И.Б., Еричев В.П. Сравнительное изучение антирадикального действия некоторых антиглаукоматозных препаратов. Вестник офтальмологии 1998; 2:6-9. [Kurysheva N.I., Deeva I.B., Erichev V.P. Comparative study of antiradical activity of some antiglaucoma drugs. Vestn Oftalmol 1998; 2:6-9. (In Russ.)].

42. Miyamoto N., Izumi H., Miyamoto R., et al. Nipradilol and timolol induce Foxo3a and peroxiredoxin 2 expression and protect trabecular meshwork cells from oxidative stress. Invest Ophthalmol Vis Sci 2009; 50(6):2777-2784.

43. Курышева Н.И., Азизова О.А., Пирязев А.П. Антирадикальная и антиоксидантная активность ингибиторов карбоангидразы для местного лечения глаукомы. Российский офтальмологический журнал 2011; 4(3):55-61. [Kurysheva N.I., Azizova O.A., Piryazev A.P. Antiradical and antioxidant activity of carbonic anhydrase inhibitors for treatment of glaucoma. Russian Ophthalmological Journal 2011; 4(3): 55-61. (In Russ.)].

44. Takano N., Tsuruma K., Ohno Y., Shimazawa M., Hara H. Bimatoprost protects retinal neuronal damage via Akt pathway. European J Pharmacol 2013; 702(1-3):56-61.

45. Watson P., Stjernschantz J. A six-month, randomized, doublemasked study comparing latanoprost with timolol in open- angle glaucoma and ocular hypertension. The Latanoprost Study Group Ophthalmology 1996; 103(1):126-137.

46. Saary K., Ali-Melkkila T., Vuory M., Iisalo E. Absorption of ocular timolol: drug concentrations and beta-receptor binding activity in the aqueous humour of the treated and contrlateral eye. Acta Ophthalmol Copenh 1993; 71(5):671-676.

47. Koevary S. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. Curr Drug Metabolism 2003; 4(3): 213-222.

48. Noecker R. The management of glaucoma and intraocular hypertension: current approaches and recent advances. Ther Clin Risk Manag 2006; 2(2):193-206.


Для цитирования:

Курышева Н.И., Азизова О.А., Пирязев А.П. Сравнительная характеристика антиоксидантной активности аналогов простагландинов для местного лечения глаукомы. Национальный журнал Глаукома. 2014;13(4):31-39.

For citation:

Kurysheva N.I., Azizova O.A., Piryazev A.P. Comparison of antioxidant activity of prostaglandin analogues for topical glaucoma treatment. National Journal glaucoma. 2014;13(4):31-39. (In Russ.)

Просмотров: 725

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2078-4104 (Print)
ISSN 2311-6862 (Online)